Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.99 is 81% above its 5-year average of -5.28, near the high end of its 5-year range (-17.16–-0.56).
51.15% below its 12-month average of -0.66.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.27.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 32 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.99
EARNINGS PER SHARE (EPS) AVG TTM
-0.66
EARNINGS PER SHARE (EPS) AVG 3Y
-3.05
EARNINGS PER SHARE (EPS) AVG 5Y
-5.28
EARNINGS PER SHARE (EPS) AVG 10Y
-13.96
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-51.15%
CURRENT VS 3Y AVG
+67.54%
CURRENT VS 5Y AVG
+81.26%
CURRENT VS 10Y AVG
+92.91%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Eledon Pharmaceuticals, Inc.
Market Cap
$186.79M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.66
3Y Avg
-3.05
5Y Avg
-5.28
Market Cap
$185.12M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.44
3Y Avg
-2.10
5Y Avg
-1.78
Market Cap
$191.14M
Earnings Per Share (EPS)
-2.46
TTM Avg
-2.12
3Y Avg
-3.30
5Y Avg
-3.30
Market Cap
$190.97M
Earnings Per Share (EPS)
-1.13
TTM Avg
-0.83
3Y Avg
-1.37
5Y Avg
-1.18
Market Cap
$182.39M
Earnings Per Share (EPS)
-1.57
TTM Avg
-5.27
3Y Avg
-99.59
5Y Avg
-93.21
Market Cap
$180.99M
Earnings Per Share (EPS)
-0.41
TTM Avg
-0.39
3Y Avg
-0.36
5Y Avg
-0.55
Market Cap
$180.31M
Earnings Per Share (EPS)
4.11
TTM Avg
0.53
3Y Avg
0.05
5Y Avg
-0.11
Market Cap
$197.57M
Earnings Per Share (EPS)
-1.10
TTM Avg
-1.31
3Y Avg
-1.45
5Y Avg
-1.45
Market Cap
$199.92M
Earnings Per Share (EPS)
-0.82
TTM Avg
-0.88
3Y Avg
-1.47
5Y Avg
-1.48
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | $186.79M | -0.99 | -0.66 | -3.05 | -5.28 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $185.12M | -1.07 | -1.44 | -2.10 | -1.78 |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $191.14M | -2.46 | -2.12 | -3.30 | -3.30 |
| RxSight, Inc. (RXST)vs › | $190.97M | -1.13 | -0.83 | -1.37 | -1.18 |
| Canton Strategic Holdings Inc (CNTN)vs › | $182.39M | -1.57 | -5.27 | -99.59 | -93.21 |
| Compass Therapeutics, Inc. (CMPX)vs › | $180.99M | -0.41 | -0.39 | -0.36 | -0.55 |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $180.31M | 4.11 | 0.53 | 0.05 | -0.11 |
| Alector, Inc. (ALEC)vs › | $197.57M | -1.10 | -1.31 | -1.45 | -1.45 |
| Exagen Inc. (XGN)vs › | $199.92M | -0.82 | -0.88 | -1.47 | -1.48 |
| Surrozen, Inc. (SRZN)vs › | $202.24M | N/A | -27.02 | -22.73 | -25.91 |
Trailing EPS (TTM)
$-0.99
Forward EPS (Est.)
$-0.95
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.56 |
| 2024-12-31 | -0.75 |
| 2023-12-31 | -4.73 |
| 2022-12-31 | -6.16 |
| 2021-12-31 | -2.33 |
| 2020-12-31 | -17.16 |
| 2019-12-31 | -24.42 |
| 2018-12-31 | -28.11 |
| 2017-12-31 | -41.40 |
| 2014-12-31 | -583.20 |
| 2013-12-31 | -112.33 |
| 2012-12-31 | -68.76 |
